News
Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...
It didn't take a high-powered academic to figure out why Scholar Rock 's (NASDAQ: SRRK) share price swooned by more than 5% ...
August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations. Reported EPS is $-0.98 EPS, expectations were $-0.66. Operator: Good morning, ladies and gentlemen, and welcome to the ...
No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...
Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases ...
Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
Scholar Rock believes that SRK-181 has the potential to overcome this immunosuppressive tumor microenvironment and induce tumor regression when administered in combination with anti-PD- (L)1 ...
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the ...
Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.
Contacts Scholar Rock: Investors Rushmie Nofsinger Scholar Rock [email protected] [email protected] 857-259-5573 Media Ariane Lovell Finn Partners [email protected] media ...
Scholar Rock management will highlight these updates in a corporate presentation at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results